Guangdong Procare Biopharmaceutical Technology

Guangdong Procare Biopharmaceutical Technology is a clinical-stage biotechnology company based in Guangzhou, China, dedicated to the research, development, and manufacturing of recombinant protein vaccines. The company utilizes a proprietary technology platform for high-yield protein expression and the development of advanced vaccine adjuvants to address significant public health challenges. Its robust pipeline features a 9-valent human papillomavirus (HPV) vaccine in Phase 3 trials, alongside candidates for herpes zoster (shingles), respiratory syncytial virus (RSV), and COVID-19. Procare is positioned as a key player in the Chinese vaccine industry, focusing on high-entry-barrier products with significant market demand.